Developer docs
API playgroundTry for free, no card

Search company profiles

Capsida Los Angeles

Full company profile

uuid0025bwb

Namestring
Capsida Los Angeles
Legal namestring
Capsida Biotherapeutics, Inc.
Websiteurl
capsida.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Capsida Biotherapeutics, Inc. is a clinical-stage, private biotechnology company developing next-generation adeno-associated virus (AAV) gene therapies for rare and common neurological and ocular diseases. Founded in 2019 in Thousand Oaks, California and based on capsid engineering technology originating from Professor Viviana Gradinaru's laboratory at Caltech, the company operates a high-throughput AAV engineering platform that screens large engineered capsid libraries in non-human primates and human cell lines to identify capsids optimized for central nervous system (CNS) and ocular delivery. Preclinical data show >100-fold improvement over AAV9 in CNS expression, >70% neuronal transduction brain-wide, and identification of novel human blood-brain-barrier receptors (ADAM15, RECK) that are conserved between primates and humans, enabling non-invasive intravenous dosing for CNS indications. The pipeline comprises CAP-001 (MPS II/Hunter Syndrome), CAP-002 (STXBP1-DEE), CAP-003 (PD-GBA), CAP-004 (Friedreich's ataxia), and a set of ophthalmology programs using intravitreal and suprachoroidal delivery. The CAP-002 SYNRGY trial was paused and subsequently closed after a patient death in September 2025, and the CAP-003 PD-GBA trial was closed in 2026; the company is repositioning around its ocular franchise and next-generation capsids.

Capsida is vertically integrated, running all process development, analytical activities, and cGMP manufacturing in a 15,000 sq ft Thousand Oaks facility using an HEK293 two-plasmid platform scalable from 2L to 200L, eliminating dependence on contract development and manufacturing organizations. The business model is a hybrid of strategic pharmaceutical partnerships and contract manufacturing: the company generates revenue from upfront payments, equity investments, milestone payments, and royalties under collaborations with AbbVie (CNS and ophthalmology, originally $80M upfront + $10M equity + $530M/program milestones + high single-digit royalties), CRISPR Therapeutics (ALS and Friedreich's ataxia), and Eli Lilly's Prevail division ($55M upfront + up to $685M in milestones + tiered royalties), supplemented by contract manufacturing revenue from Kate Therapeutics. The platform can deliver gene replacement, gene editing, gene silencing, and vectorized antibody cargos.

The company is financed by Versant Ventures and Westlake Village BioPartners, both of which co-led the April 2021 $50M Series A alongside a $90M AbbVie strategic collaboration, and has an issued U.S. patent (11,149,256) covering brain-wide transducing capsids with reduced liver targeting plus 30-40+ pending patent applications. Leadership includes Interim CEO Mina Kim (former CEO and CLO of Acelyrin), CSO Romuald Corbau (ex-CSO of Adverum Biotechnologies, acquired by Eli Lilly), CFO Amar Duvvur (former SVP Finance at Acelyrin, VP at AbbVie), co-founder Nicholas Flytzanis (Chief Research and Innovation Officer), and Chief Manufacturing and Quality Officer Rob Murphy, with board representation from Versant (Clare Ozawa), Westlake (Beth Seidenberg), and independent directors Rita Balice-Gordon and Frank Verwiel. Headcount is reported at 50-100 employees.

Short descriptiontext

Capsida Biotherapeutics is a clinical-stage gene therapy company engineering AAV capsids for targeted delivery to the central nervous system and eye. It develops treatments for neurological and ocular diseases via internal programs and strategic partnerships with major pharmaceutical companies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersNewbury Park, United States
HQ citystring
Newbury Park
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AAV gene therapy, capsid engineering platform, CNS disease therapeutics, ocular gene therapy, biologics manufacturing
Industry4 codes
PRIMARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biotechnology - Gene Therapy
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Strategic Partnerships and Licensing
TypeLicensing Royalties
Description

Capsida receives upfront payments, equity investments, and milestone payments from pharmaceutical partners (AbbVie, CRISPR Therapeutics, Lilly/Prevail) for developing gene therapies using its AAV platform

capsida.com
2Collaboration Revenue
TypeLicensing Royalties
Description

Revenue from strategic collaborations including option fees, development milestones, and commercial royalties. AbbVie collaboration includes $530M per program in option and development milestones plus high single-digit royalties. Prevail collaboration includes up to $685M in R&D and commercial milestones plus tiered royalties

capsida.com
3Internal Pipeline Development
TypeLicensing Royalties
Description

Development of proprietary gene therapy programs (CAP-002, CAP-003, CAP-004) for rare and common neurological diseases targeting future commercial revenue

capsida.com
4Contract Manufacturing
TypeProfessional Services
Description

Manufacturing services for external partners including Kate Therapeutics for next-generation gene therapies

capsida.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Infrastructure, Supply Chain, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Capsida Biotherapeutics is a fully integrated genetic medicine company developing engineered adeno-associated virus (AAV) capsids and gene therapies targeting rare and common neurological and ocular diseases. Its core offering is a high-throughput capsid engineering platform that screens billions of engineered capsid variants in non-human primates to identify capsids capable of crossing the blood-brain barrier with intravenous delivery, combined with an internal pipeline of gene therapy programs (CAP-001, CAP-002, CAP-003, CAP-004) and proprietary cGMP manufacturing capabilities.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • >100-fold improvement over AAV9 in CNS expression in NHPs
+3 more records
Product overview1 text field

Capsida Biotherapeutics is a fully integrated next-generation genetic medicine company developing a pipeline of gene therapies for rare and common neurologic and ocular diseases. The company's core offering consists of its proprietary AAV Capsid Engineering Platform, which enables the development of engineered capsids for targeted gene delivery. The integrated pipeline includes: CAP-001 (MPS II), CAP-002 (STXBP1-DEE), CAP-003 (PD-GBA), and CAP-004 (Friedreich's ataxia), alongside ophthalmology programs utilizing IVT and SCS delivery routes. The company operates state-of-the-art cGMP manufacturing facilities for end-to-end production control.

Product and service6 records
1CAP-001
CategoryGene therapy program
Description

Engineered AAV gene therapy for MPS II (Hunter Syndrome), a lysosomal storage disorder, delivering IDS transgene using novel capsid technology.

2CAP-002
CategoryGene therapy program
Description

IV-delivered AAV gene therapy for STXBP1 Developmental and Epileptic Encephalopathy (STXBP1-DEE), designed to stably replace STXBP1 protein throughout the brain after single intravenous infusion.

3CAP-003
CategoryGene therapy program
Description

IV-delivered AAV gene therapy for Parkinson's disease associated with GBA mutations (PD-GBA), designed to increase GCase activity in the brain.

4CAP-004
CategoryGene therapy program
Description

Gene therapy for Friedreich's ataxia targeting CNS and cardiac symptoms, delivered as single intravenous infusion addressing underlying frataxin deficiency.

5Capsid Engineering Platform
CategoryTechnology platform
Description

High-throughput AAV engineering platform using automated screening of large diverse engineered capsid libraries in non-human primates to identify optimal capsids for CNS and ocular targets.

6cGMP Manufacturing Services
CategoryManufacturing capability
Description

State-of-the-art cGMP manufacturing operations using HEK293 platform with two-plasmid transfection system, scalable from 2L to 200L, supporting IND packages and contract manufacturing for external partners.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2023-10-03
Description

Strategic collaboration for Capsida to manufacture KateTx's next-generation gene therapies, leveraging state-of-the-art cGMP manufacturing capabilities

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-04
Description

Multi-year collaboration to develop IV-administered gene therapies for CNS diseases using Capsida's AAV platform. Capsida receives $55M upfront plus potential up to $685M in milestones and royalties. Capsida leads capsid discovery; Prevail handles preclinical and IND-enabling studies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-06-15
Description

Strategic partnership to research, develop, manufacture and commercialize in vivo gene editing therapies for familial ALS and Friedreich's ataxia. CRISPR leads Friedreich's ataxia program and gene-editing; Capsida leads ALS program and capsid engineering. Each company has option to co-develop and co-commercialize the program the other leads.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-04-29
Description

Multi-year strategic collaboration to develop best-in-class, targeted gene therapies for three CNS disease targets. Capsida receives $80M upfront + $10M equity, eligible for $530M per program in milestones plus high single-digit royalties. AbbVie leads late-stage development and commercialization. Collaboration expanded in 2023 to include three ophthalmology programs.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

BioMarin is a commercial-stage rare disease biotech with the first FDA-approved AAV gene therapy (ROCTAVIAN for hemophilia A). It is a broad incumbent in gene therapy commercialization with CNS and rare disease pipeline overlap with Capsida.

TypeBroad incumbent
Description

Spark, a Roche subsidiary, commercialized LUXTURNA (first FDA-approved AAV gene therapy) and develops gene therapies for CNS, ophthalmic, and hematologic indications. It is a broad incumbent in the AAV gene therapy space overlapping Capsida's ocular and rare disease focus.

TypeDirect peer
Description

Taysha develops AAV gene therapies for CNS diseases including Rett syndrome and GAN, directly overlapping with Capsida's CNS pipeline. Similar clinical-stage profile and reliance on partnership economics to advance pipeline.

TypeDirect peer
Description

Adverum (acquired by Eli Lilly in 2024) developed intravitreal AAV gene therapies for ocular diseases, directly competing with Capsida's ocular capsid programs. Capsida's new CSO Romuald Corbau was previously CSO at Adverum, underscoring the strategic linkage.

TypeEmerging player
Description

Krystal Biotech is a commercial-stage gene therapy company (VYJUVEK for DEB) with a delivery platform applicable to rare diseases. Smaller and more focused than Capsida, it provides a comp on rare-disease gene therapy commercial economics.

TypeBroad incumbent
Description

Sarepta is the leading commercial gene therapy company with multiple approved AAV micro-dystrophin products for Duchenne muscular dystrophy. It represents the established commercial benchmark and potential acquirer/partner for capsid-engineered CNS assets.

TypeDirect peer
Description

uniQure is an AAV-based gene therapy company with commercial product HEMGENIX (hemophilia B) and pipeline assets in Huntington's disease (similar CNS focus to Capsida) and other indications. Direct comparable on modality and CNS target space.

TypeDirect peer
Description

Voyager is a leading AAV capsid engineering company with a TRACER-derived capsid platform for CNS and other indications. It is the most direct competitor to Capsida's engineered-AAV-for-CNS thesis and has similar partnership economics with Pfizer, Novartis, and others.

TypeDirect peer
Description

REGENXBIO develops AAV gene therapies using its NAV Technology Platform across rare and chronic diseases including CNS, retinal, and metabolic indications. It is a direct peer on the AAV platform and delivery side, with commercial-stage product ABECMA-related royalty stream and clinical pipeline overlap with Capsida.

TypeBroad incumbent
Description

Pfizer is a broad biopharmaceutical incumbent with AAV gene therapy assets (e.g., beqvez for hemophilia B) and Capsida's new CSO Romuald Corbau initiated Pfizer's first gene therapy program. Functions as both a potential partner/acquirer and a competitor in CNS AAV delivery.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Capsida Los Angeles

Biotechnology - Gene Therapycapsida.com

Capsida Biotherapeutics is a clinical-stage gene therapy company engineering AAV capsids for targeted delivery to the central nervous system and eye. It develops treatments for neurological and ocular diseases via internal programs and strategic partnerships with major pharmaceutical companies.

What Capsida Los Angeles does

Capsida Biotherapeutics, Inc. is a clinical-stage, private biotechnology company developing next-generation adeno-associated virus (AAV) gene therapies for rare and common neurological and ocular diseases. Founded in 2019 in Thousand Oaks, California and based on capsid engineering technology originating from Professor Viviana Gradinaru's laboratory at Caltech, the company operates a high-throughput AAV engineering platform that screens large engineered capsid libraries in non-human primates and human cell lines to identify capsids optimized for central nervous system (CNS) and ocular delivery. Preclinical data show >100-fold improvement over AAV9 in CNS expression, >70% neuronal transduction brain-wide, and identification of novel human blood-brain-barrier receptors (ADAM15, RECK) that are conserved between primates and humans, enabling non-invasive intravenous dosing for CNS indications. The pipeline comprises CAP-001 (MPS II/Hunter Syndrome), CAP-002 (STXBP1-DEE), CAP-003 (PD-GBA), CAP-004 (Friedreich's ataxia), and a set of ophthalmology programs using intravitreal and suprachoroidal delivery. The CAP-002 SYNRGY trial was paused and subsequently closed after a patient death in September 2025, and the CAP-003 PD-GBA trial was closed in 2026; the company is repositioning around its ocular franchise and next-generation capsids.

Capsida is vertically integrated, running all process development, analytical activities, and cGMP manufacturing in a 15,000 sq ft Thousand Oaks facility using an HEK293 two-plasmid platform scalable from 2L to 200L, eliminating dependence on contract development and manufacturing organizations. The business model is a hybrid of strategic pharmaceutical partnerships and contract manufacturing: the company generates revenue from upfront payments, equity investments, milestone payments, and royalties under collaborations with AbbVie (CNS and ophthalmology, originally $80M upfront + $10M equity + $530M/program milestones + high single-digit royalties), CRISPR Therapeutics (ALS and Friedreich's ataxia), and Eli Lilly's Prevail division ($55M upfront + up to $685M in milestones + tiered royalties), supplemented by contract manufacturing revenue from Kate Therapeutics. The platform can deliver gene replacement, gene editing, gene silencing, and vectorized antibody cargos.

The company is financed by Versant Ventures and Westlake Village BioPartners, both of which co-led the April 2021 $50M Series A alongside a $90M AbbVie strategic collaboration, and has an issued U.S. patent (11,149,256) covering brain-wide transducing capsids with reduced liver targeting plus 30-40+ pending patent applications. Leadership includes Interim CEO Mina Kim (former CEO and CLO of Acelyrin), CSO Romuald Corbau (ex-CSO of Adverum Biotechnologies, acquired by Eli Lilly), CFO Amar Duvvur (former SVP Finance at Acelyrin, VP at AbbVie), co-founder Nicholas Flytzanis (Chief Research and Innovation Officer), and Chief Manufacturing and Quality Officer Rob Murphy, with board representation from Versant (Clare Ozawa), Westlake (Beth Seidenberg), and independent directors Rita Balice-Gordon and Frank Verwiel. Headcount is reported at 50-100 employees.

Capsida Los Angeles firmographics

Firmographics
Name
Capsida Los Angeles
Legal name
Capsida Biotherapeutics, Inc.
Website
https://capsida.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
51–100 employees
Short description
Capsida Biotherapeutics is a clinical-stage gene therapy company engineering AAV capsids for targeted delivery to the central nervous system and eye. It develops treatments for neurological and ocular diseases via internal programs and strategic partnerships with major pharmaceutical companies.
Ownership category
akta.pro rank

Capsida Los Angeles industry classification

Industry
Product category
Biotechnology - Gene Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAA
AAV Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAL
Gene Therapy Delivery Devices & Administration Systems (catheters, intrathecal, ocular delivery)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • AAV gene therapy
  • Capsid engineering platform
  • CNS disease therapeutics
  • Ocular gene therapy
  • Biologics manufacturing

Where Capsida Los Angeles is headquartered

Location

Headquarters

HQ city
Newbury Park
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Capsida Los Angeles business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Infrastructure, Supply Chain, Operations

Revenue model

  1. Strategic Partnerships and Licensing: Capsida receives upfront payments, equity investments, and milestone payments from pharmaceutical partners (AbbVie, CRISPR Therapeutics, Lilly/Prevail) for developing gene therapies using its AAV platform
  2. Collaboration Revenue: Revenue from strategic collaborations including option fees, development milestones, and commercial royalties. AbbVie collaboration includes $530M per program in option and development milestones plus high single-digit royalties. Prevail collaboration includes up to $685M in R&D and commercial milestones plus tiered royalties
  3. Internal Pipeline Development: Development of proprietary gene therapy programs (CAP-002, CAP-003, CAP-004) for rare and common neurological diseases targeting future commercial revenue
  4. Contract Manufacturing: Manufacturing services for external partners including Kate Therapeutics for next-generation gene therapies

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Capsida Los Angeles product offering

Product offering

Core offering

Capsida Biotherapeutics is a fully integrated genetic medicine company developing engineered adeno-associated virus (AAV) capsids and gene therapies targeting rare and common neurological and ocular diseases. Its core offering is a high-throughput capsid engineering platform that screens billions of engineered capsid variants in non-human primates to identify capsids capable of crossing the blood-brain barrier with intravenous delivery, combined with an internal pipeline of gene therapy programs (CAP-001, CAP-002, CAP-003, CAP-004) and proprietary cGMP manufacturing capabilities.

Product overview

Capsida Biotherapeutics is a fully integrated next-generation genetic medicine company developing a pipeline of gene therapies for rare and common neurologic and ocular diseases. The company's core offering consists of its proprietary AAV Capsid Engineering Platform, which enables the development of engineered capsids for targeted gene delivery. The integrated pipeline includes: CAP-001 (MPS II), CAP-002 (STXBP1-DEE), CAP-003 (PD-GBA), and CAP-004 (Friedreich's ataxia), alongside ophthalmology programs utilizing IVT and SCS delivery routes. The company operates state-of-the-art cGMP manufacturing facilities for end-to-end production control.

Differentiator

Problem solved

Functional benefit

Products and services

  • CAP-001 Engineered AAV gene therapy for MPS II (Hunter Syndrome), a lysosomal storage disorder, delivering IDS transgene using novel capsid technology.
  • CAP-002 IV-delivered AAV gene therapy for STXBP1 Developmental and Epileptic Encephalopathy (STXBP1-DEE), designed to stably replace STXBP1 protein throughout the brain after single intravenous infusion.
  • CAP-003 IV-delivered AAV gene therapy for Parkinson's disease associated with GBA mutations (PD-GBA), designed to increase GCase activity in the brain.
  • CAP-004 Gene therapy for Friedreich's ataxia targeting CNS and cardiac symptoms, delivered as single intravenous infusion addressing underlying frataxin deficiency.
  • Capsid Engineering Platform High-throughput AAV engineering platform using automated screening of large diverse engineered capsid libraries in non-human primates to identify optimal capsids for CNS and ocular targets.
  • cGMP Manufacturing Services State-of-the-art cGMP manufacturing operations using HEK293 platform with two-plasmid transfection system, scalable from 2L to 200L, supporting IND packages and contract manufacturing for external partners.

Quantifiable outcome

  • >100-fold improvement over AAV9 in CNS expression in NHPs
  • +3 more outcomes

Companies that use Capsida Los Angeles

Customer profile

Named customers4 records

Segments6 records

Ideal customer profiles2 records

Capsida Los Angeles technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Capsida Los Angeles partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered minor and core.

  • Kate TherapeuticsminorImplementation/ SI/ Consulting Partner · 3 October 2023Strategic collaboration for Capsida to manufacture KateTx's next-generation gene therapies, leveraging state-of-the-art cGMP manufacturing capabilities
  • Prevail Therapeutics (Eli Lilly)coreStrategic or Co-development Partner · 4 January 2023Multi-year collaboration to develop IV-administered gene therapies for CNS diseases using Capsida's AAV platform. Capsida receives $55M upfront plus potential up to $685M in milestones and royalties. Capsida leads capsid discovery; Prevail handles preclinical and IND-enabling studies.
  • CRISPR TherapeuticscoreStrategic or Co-development Partner · 15 June 2021Strategic partnership to research, develop, manufacture and commercialize in vivo gene editing therapies for familial ALS and Friedreich's ataxia. CRISPR leads Friedreich's ataxia program and gene-editing; Capsida leads ALS program and capsid engineering. Each company has option to co-develop and co-commercialize the program the other leads.
  • AbbViecoreStrategic or Co-development Partner · 29 April 2021Multi-year strategic collaboration to develop best-in-class, targeted gene therapies for three CNS disease targets. Capsida receives $80M upfront + $10M equity, eligible for $530M per program in milestones plus high single-digit royalties. AbbVie leads late-stage development and commercialization. Collaboration expanded in 2023 to include three ophthalmology programs.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Capsida Los Angeles competitors and assessment

Company assessment

Broad incumbents

  • BioMarin Pharmaceutical: BioMarin is a commercial-stage rare disease biotech with the first FDA-approved AAV gene therapy (ROCTAVIAN for hemophilia A). It is a broad incumbent in gene therapy commercialization with CNS and rare disease pipeline overlap with Capsida.
  • Spark Therapeutics (Roche): Spark, a Roche subsidiary, commercialized LUXTURNA (first FDA-approved AAV gene therapy) and develops gene therapies for CNS, ophthalmic, and hematologic indications. It is a broad incumbent in the AAV gene therapy space overlapping Capsida's ocular and rare disease focus.
  • Sarepta Therapeutics: Sarepta is the leading commercial gene therapy company with multiple approved AAV micro-dystrophin products for Duchenne muscular dystrophy. It represents the established commercial benchmark and potential acquirer/partner for capsid-engineered CNS assets.
  • Pfizer (Gene Therapy Unit): Pfizer is a broad biopharmaceutical incumbent with AAV gene therapy assets (e.g., beqvez for hemophilia B) and Capsida's new CSO Romuald Corbau initiated Pfizer's first gene therapy program. Functions as both a potential partner/acquirer and a competitor in CNS AAV delivery.

Direct peers

  • Taysha Gene Therapies: Taysha develops AAV gene therapies for CNS diseases including Rett syndrome and GAN, directly overlapping with Capsida's CNS pipeline. Similar clinical-stage profile and reliance on partnership economics to advance pipeline.
  • Adverum Biotechnologies: Adverum (acquired by Eli Lilly in 2024) developed intravitreal AAV gene therapies for ocular diseases, directly competing with Capsida's ocular capsid programs. Capsida's new CSO Romuald Corbau was previously CSO at Adverum, underscoring the strategic linkage.
  • uniQure: uniQure is an AAV-based gene therapy company with commercial product HEMGENIX (hemophilia B) and pipeline assets in Huntington's disease (similar CNS focus to Capsida) and other indications. Direct comparable on modality and CNS target space.
  • Voyager Therapeutics: Voyager is a leading AAV capsid engineering company with a TRACER-derived capsid platform for CNS and other indications. It is the most direct competitor to Capsida's engineered-AAV-for-CNS thesis and has similar partnership economics with Pfizer, Novartis, and others.
  • REGENXBIO: REGENXBIO develops AAV gene therapies using its NAV Technology Platform across rare and chronic diseases including CNS, retinal, and metabolic indications. It is a direct peer on the AAV platform and delivery side, with commercial-stage product ABECMA-related royalty stream and clinical pipeline overlap with Capsida.

Emerging players

  • Krystal Biotech: Krystal Biotech is a commercial-stage gene therapy company (VYJUVEK for DEB) with a delivery platform applicable to rare diseases. Smaller and more focused than Capsida, it provides a comp on rare-disease gene therapy commercial economics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

Capsida Los Angeles social profiles

Digital presence

Capsida Los Angeles compliance and trust

Trust signal

Compliance4 records

Capsida Los Angeles financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Capsida Los Angeles leadership team

Management profile

Number of profiles

Profiles9 records

Capsida Los Angeles funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Capsida Los Angeles M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Capsida Los Angeles

What does Capsida Los Angeles do?

Capsida Biotherapeutics is a fully integrated genetic medicine company developing engineered adeno-associated virus (AAV) capsids and gene therapies targeting rare and common neurological and ocular diseases. Its core offering is a high-throughput capsid engineering platform that screens billions of engineered capsid variants in non-human primates to identify capsids capable of crossing the blood-brain barrier with intravenous delivery, combined with an internal pipeline of gene therapy programs (CAP-001, CAP-002, CAP-003, CAP-004) and proprietary cGMP manufacturing capabilities.

Is Capsida Los Angeles a public or private company?

Capsida Los Angeles is a private company. It is classified as venture growth investor backed and is currently operating.

When was Capsida Los Angeles founded?

Capsida Los Angeles was founded in 2019. It employs 51 to 100 people.

Where is Capsida Los Angeles based?

Capsida Los Angeles is headquartered in Newbury Park, United States, in the North America region.

How does Capsida Los Angeles make money?

Four revenue lines are on record. Strategic Partnerships and Licensing is the primary driver. The others are collaboration Revenue, internal Pipeline Development and contract Manufacturing.

Who are Capsida Los Angeles's main competitors?

Broad incumbents on record are BioMarin Pharmaceutical, Spark Therapeutics (Roche), Sarepta Therapeutics and Pfizer (Gene Therapy Unit). Direct peers are Taysha Gene Therapies, Adverum Biotechnologies, uniQure, Voyager Therapeutics and REGENXBIO. Krystal Biotech is listed as an emerging player.

Does Capsida Los Angeles have an API?

No public API is recorded for Capsida Los Angeles.

What industry is Capsida Los Angeles in?

Capsida Los Angeles's product category is Biotechnology - Gene Therapy. Its primary akta.pro industry code is HLAAACAN, Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream), with a secondary code of HLAAACAA, AAV Vector Gene Therapy Developers. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireFDA Grants Orphan Drug Designation to Capsida Biotherapeutics for Potential Treatment of STXBP1 Developmental and Epileptic EncephalopathyThe FDA granted Orphan Drug Designation to Capsida Biotherapeutics for CAP-002, a gene therapy for STXBP1 developmental and epileptic encephalopathy. The company plans to file an IND in the first half of 2025, with the therapy expected to enter clinical trials in the same period.GlobeNewswireCRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich’s AtaxiaCRISPR Therapeutics and Capsida Biotherapeutics announced a strategic partnership to develop gene-edited therapies for familial ALS and Friedreich's ataxia using AAV vectors. CRISPR will lead the Friedreich's program and gene editing, while Capsida leads ALS and capsid engineering, with options to co-develop and share costs and profits equally.FinSMEsCapsida Biotherapeutics Raises $140M in Series A FundingCapsida Biotherapeutics raised $140M in Series A funding, with $50M from Versant Ventures and Westlake Village BioPartners. It also announced a $90M collaboration with AbbVie for three neurodegenerative disease programs, including $80M upfront and $530M in milestones. The company expects to start IND-enabling work in 2021 and clinical trials in 2022.PR NewswireCapsida Biotherapeutics Debuts with $140 Million of CapitalCapsida Biotherapeutics emerged from stealth with a $50 million Series A from Versant Ventures and Westlake Village BioPartners, plus a $90 million AbbVie collaboration. The deal includes $80 million upfront and $10 million equity, with potential milestone payments up to $530 million for two CNS targets. Capsida expects IND-enabling work in 2021 and clinical trials in 2022.